Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > My Guess

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on May 14, 2020 2:39pm

117 Views

Post# 31029013

RE:RE:My Guess

IamFloored wrote: I have yet to profit from a company with a reverse split. Most companies do this to boost SP and issue more outstanding shares. In so doing, they toss their previous common shareholders to the curb. Combine the reverse split with a company that has no fundamentals and it spells disaster. Common accounting trick for companies on the sly and to profit internally themselves by raising equity via paper.

..there were talks of RS ... but was it made official?... no... Let's see what this NR brings ...

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages